NANOBIOTIX Announces Updated Preliminary Results From Phase

Strategic Collaborator-presented Phase 1 Pancreatic Cancer Data An ongoing Phase 1, collaborator-led study of NBTXR3 in locally advanced pancreatic cancer established a favorable safety profile and...

Related Keywords

Texas , United States , Massachusetts , China , Paris , France General , France , Cambridge , Cambridgeshire , United Kingdom , New York , Pierre Louis Germain , Christophe Le Tourneau , Brandon Owens , Louis Kayitalire , Ligia Vela Reid , Exchange Commission , Given The Company , Linkedin , Drug Administration , Nasdaq , Investor Relations Department , University Of Texas Md Anderson Cancer Center , French Financial Markets Authority Autorit , Euronext , Twitter , European Society For Medical Oncology , Communications Department , Strategic Collaborator Presented Phase , Overall Survival , All Patients Treated , Objective Response , Progression Free Survival , European Society , Medical Oncology , Endoscopic Ultrasound , Locally Advanced , Borderline Resectable Pancreatic Cancer , Cancer Center , Antitumor Activity , Injected Lesions , Estimate Overall Survival , Exploratory Analyses , Cisplatin Ineligible Locally Advanced , Local Progression Free Survival , Professor Christophe Le Tourneau , United States Food , Fast Track , Greater China , Asian Markets , Janssen Pharmaceutica , Euronext Paris , Nasdaq Global Select Market , New York City , Private Securities Litigation Reform Act , Annual Report , French Financial Markets Authority , Des March , Markets ,